$JNJ News

Johnson & Johnson to Host Enterprise Business Review

What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock?

ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data

Johnson & Johnson Prostate Cancer Drug Shrinks Tumors In Early Stage Trial

Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

J&J’s Smith & Nephew Deal Collapsed Over One Executive. Here’s What It Means for the DePuy Spin

Smith And Nephew Merger Talks With Johnson & Johnson Collapse Over Leadership Dispute

Correction: Update: Market Chatter: Johnson & Johnson Orthopedics, Smith & Nephew Merger Collapsed Over Leadership Dispute

Johnson & Johnson (JNJ) Stock Gets Fair Value Bump On Mixed Analyst Target Changes

Johnson & Johnson's Icotrokinra Hydrochloride Receives Medicines And Healthcare Products Regulatory Agency Approval To Treat Moderate To Severe Plaque Psoriasis

Johnson & Johnson Jumps 4.4% as VARIPULSE Pro Hits 100% Procedural Success

Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration

JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up

Is Johnson & Johnson Stock Ready For A MedTech Stall?

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed

Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?